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Abstract 
Background: The pathophysiological basis of idiopathic normal pressure hydrocephalus (iNPH) is still unclear. Previ-
ous studies have shown a familial aggregation and a potential heritability when it comes to iNPH. Our aim was to 
conduct a novel case-controlled comparison between familial iNPH (fNPH) patients and their elderly relatives, involv-
ing multiple different families.
Methods: Questionnaires and phone interviews were used for collecting the data and categorising the iNPH patients 
into the familial (fNPH) and the sporadic groups. Identical questionnaires were sent to the relatives of the potential 
fNPH patients. Venous blood samples were collected for genetic studies. The disease histories of the probable fNPH 
patients (n = 60) were compared with their ≥ 60-year-old relatives with no iNPH (n = 49). A modified Charlson Comor-
bidity Index (CCI) was used to measure the overall disease burden. Fisher’s exact test (two-tailed), the Mann–Whitney 
U test (two-tailed) and a multivariate binary logistic regression analysis were used to perform the statistical analyses.
Results: Diabetes (32% vs. 14%, p = 0.043), arterial hypertension (65.0% vs. 43%, p = 0.033), cardiac insufficiency (16% 
vs. 2%, p = 0.020) and depressive symptoms (32% vs. 8%, p = 0.004) were overrepresented among the probable fNPH 
patients compared to their non-iNPH relatives. In the age-adjusted multivariate logistic regression analysis, diabetes 
remained independently associated with fNPH (OR = 3.8, 95% CI 1.1–12.9, p = 0.030).
Conclusions: Diabetes is associated with fNPH and a possible risk factor for fNPH. Diabetes could contribute to the 
pathogenesis of iNPH/fNPH, which motivates to further prospective and gene-environmental studies to decipher the 
disease modelling of iNPH/fNPH.
Keywords: Normal pressure hydrocephalus, Familial, Comorbidities, Diabetes, Depression, Genetics, SFMBT1
© The Author(s) 2020. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, 
adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and 
the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material 
in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material 
is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the 
permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco 
mmons .org/licen ses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creat iveco mmons .org/publi cdoma in/
zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Background
Idiopathic normal pressure hydrocephalus (iNPH) is a 
chronic and progressive neurological disorder among 
the elderly [1, 2]. It is characterised by ventriculomeg-
aly in neuroradiological imaging and gait disturbances, 
while cognitive decline and urinary incontinence are also 
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commonly observed [1, 2]. INPH is treated with a cere-
brospinal fluid (CSF) shunt surgery with moderate long-
term outcome [3]. In recent meta-analyses, the overall 
prevalence of iNPH was found to be around 175/100,000 
among the elderly and the annual incidence around 1.1–
5.5/100,000 [4, 5]. However, a recent prospective popu-
lation-based study from Sweden found the prevalence 
of iNPH among the elderly to be as high as 3.7% and 
increasing with age [6]. Previous studies have suggested 
cardiovascular risk factors to be associated with the 
pathology of iNPH [7–15], while the precise pathophysi-
ological basis of iNPH is still unknown [2].
The familial occurrence of iNPH has been previously 
established [16–26], with some of the drawn pedigrees 
showing signs of autosomal dominant inheritance. Out of 
all iNPH patients, 7–16% have been discovered to have 
symptomatic or shunted relatives [23, 25]. The familial 
iNPH (fNPH) cases have also been found to slightly dif-
fer from the sporadic ones, with potentially more severe 
symptoms [25]. This all suggests that iNPH could pos-
sibly have a heritable form with an independent genetic 
background or have a familial subgroup, i.e. fNPH [25], 
but only a few possible risk genes have yet been found. 
Most promisingly, copy number (CN) loss in intron 2 of 
the SFMBT1 gene has been reported as being overrep-
resented among the iNPH patients in Japanese, Finnish 
and Norwegian study cohorts [27, 28]. Also, a loss-of-
function mutation in CFAP43 has been found in a Japa-
nese family with multiple iNPH cases [29]. Interestingly, 
the SFMBT1 protein has been shown to be present in the 
structures vital for the CSF dynamics such as the choroid 
plexus [30], and the CFAP43-deficient mice exhibited 
hydrocephalus and cilia abnormalities [29]. APOE ε4 is 
not associated with the development of iNPH but is com-
monly seen in the iNPH patients with comorbid Alzhei-
mer’s disease (AD) [31, 32].
The aim of this study was to conduct a case-con-
trolled comparison of the fNPH patients to their elderly 
non-iNPH relatives. By comparing people with simi-
lar environmental and genetic backgrounds, important 
information regarding the comorbidities and the possible 
risk factors of developing iNPH can be acquired [33]. The 
possible heritability of iNPH is a notable addition to the 
previously reported findings regarding the cardiovascular 
risk factors in iNPH [7–15].
Methods
Data collection and the selection of the participants
The collection of the data is described in detail in a pre-
vious study that compared the fNPH patients and the 
sporadic iNPH patients against each other [25]. The 
same data was used in this study for the fNPH patients 
with some new cases as the data collection and the 
patient recruitment were continued afterwards. A ret-
rospective recruitment of the iNPH patients from all 
neurosurgical units in Finland, shunted since 1993, 
was performed. The iNPH patients were searched from 
these registries based on both operative procedure 
codes and diagnostic codes (ICD 10; G91.2).
Until the June of 2020, altogether 1349 patients were 
sent a questionnaire inquiring on their medical condi-
tions and possible family symptomatology, from which 
718 (53.2%) were returned with informed consent. The 
medical records of the possible and probable iNPH 
patients with returned questionnaires were reviewed 
by the study neurosurgeon of the corresponding unit 
to exclude secondary normal pressure hydrocephalus 
(sNPH) [1, 2]. Altogether, 100 patients were discovered 
to have a potential secondary cause of NPH indicated 
in the medical records and they were excluded from 
the study. The final number of the iNPH patients with 
a returned questionnaire and informed consent was 
618 (45.8%) (index patients). The 6-page questionnaire 
(Additional file 1) contained questions related to iNPH, 
comorbidities, physical condition, alcohol drinking, 
smoking and a brief family anamnesis of relatives with a 
possible iNPH-symptomatology. It also contained ques-
tions on medications which were used to cross-check 
the validity of the answers when available.
INPH was considered potentially familial (fNPH) if 
the index patient reported at least one relative with ≥ 2 
symptoms of the triad or a diagnosed iNPH. These 
potentially familial iNPH patients were phone-inter-
viewed to exclude the possibility of a known etiology 
other than iNPH causing the relative’s symptoms. An 
identical questionnaire was sent to those relatives will-
ing to participate in the study. The relatives were first 
contacted by the index patient or their next of kin. The 
questionnaire was sent only to the relatives of those 
iNPH patients whose iNPH was considered potentially 
familial. The relatives reporting the triad symptoms 
were also phone-interviewed about their symptoms.
Out of the 618 iNPH index patients, 96 (15.5%) were 
found to potentially have a familial iNPH (fNPH), which 
is in line with previous studies [23, 25]. These poten-
tial fNPH patients were found in 79 different families. 
Altogether 288 relatives were sent the questionnaire 
and 170 (59.0%) returned it with an informed consent. 
Approximately three-generation pedigrees were drawn 
from these fNPH families based on the phone inter-
views and the questionnaire information. Venous blood 
samples were also collected from the participants to be 
used for genetic studies. All participants included in 
the study were selected independent of the exposure of 
interest to avoid selection bias [34, 35].
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Categorisation of the patients and their relatives
The potential fNPH index patients were then divided into 
two categories based on the probability of them truly 
having multiple iNPH/fNPH cases in the family. A prob-
able fNPH index patient (n = 55) had at least one relative 
with a diagnosed iNPH or the relative had brain-imaging 
available with findings (ventriculomegaly, narrowing of 
the sulci and often disproportionately enlarged suba-
rachnoid space hydrocephalus) and symptoms indicative 
of iNPH [1, 2]. The number of the probable fNPH fami-
lies was 39. The remaining patients with potential fNPH 
were considered iNPH patients with at least one relative 
with ≥ 2 symptoms of the triad caused by an unknown 
etiology but the relative had no brain-imaging available 
to reliably confirm iNPH (n = 41) (Fig. 1). The number of 
these families was 40.
The relatives returning the questionnaire were catego-
rised as symptomatic or asymptomatic, based on whether 
they had symptoms of the triad, and as the shunted iNPH 
patients (Fig. 2).
Formation of comparable groups
The aim of the study was to compare the fNPH patients to 
their elderly non-iNPH relatives. The groups in the final 
analysis were “Probable fNPH patients” (n = 60) and the 
control group of “Non-iNPH relatives, age ≥ 60” (n = 49) 
(Tables  3 and 4). Only the probable fNPH patients and 
their relatives were included to the final analysis as these 
families have multiple iNPH (fNPH) cases that we were 
able to reliably confirm. The iNPH patients with symp-
tomatic relatives without brain-imaging available to reli-
ably confirm the relative to truly suffer from iNPH were 
excluded from the final analysis as well as their healthy 
relatives (Fig. 2).
The group of “Probable fNPH patients” (n = 60) was 
formed from the probable fNPH index patients (n = 55) 
and their relatives with a shunted iNPH and a returned 
questionnaire (n = 7). The medical records of these 
relatives with shunted iNPH were also re-evaluated to 
exclude sNPH. Those with inadequately filled question-
naires were excluded (n = 2). All the patients in this cat-
egory had a diagnosed and shunted iNPH.
The control group of “Non-iNPH relatives, age ≥ 60” 
(n = 49) consisted of only the relatives of the probable 
fNPH patients that were ≥ 60 years old, asymptomatic or 
had a confirmed cause other than iNPH for their symp-
toms and had an adequately filled questionnaire. The 
relatives under the age of 60 were excluded to match the 
age range of the control group with the late average onset 
age of iNPH. The symptomatic relatives with indefinite 
triad symptoms or iNPH without a shunt were excluded. 
Also, those with inadequately filled questionnaires were 
excluded (Fig. 2). The control group consisted of 19 sis-
ters, 15 brothers, 2 daughters, 1 uncle, 7 nieces and 5 
nephews of the probable fNPH index patients.
Summary of the terms related to NPH and the descrip-
tion of different groups are shown in the Table  1 and 
the iNPH-related characteristics of the probable fNPH 
patients included in the final analyses are shown in the 
Table 2.
APOE and SFMBT1 genotyping
Genomic DNA was extracted from the venous blood 
samples with the QIAamp DNA blood mini extraction 
Fig. 1 How the shunted possible or probable iNPH patients (index patients) were divided into the familial (fNPH) and the sporadic categories
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kit (QIAGEN). APOE was genotyped from 45/60 (75%) 
of the probable fNPH patients and from 25/49 (51%) 
of their ≥ 60-year-old non-iNPH relatives by deter-
mining 2 single-nucleotide polymorphisms (rs429358 
and rs7412) by using the polymerase chain reaction 
(PCR), the TaqMan genotyping assays (Applied Bio-
systems (ABI), Foster City, CA, USA) and an allelic 
discrimination method on the ABI 7000 platform [36]. 
Possible CN loss in intron 2 of the SFMBT1 gene was 
Fig. 2 How the compared groups in the final analysis were formed based on the questionnaires and the phone interviews. The dashed lines and 
the boxes with dashed borders indicate exclusion from the final analysis. The left side of the figure shows how the group of “Probable fNPH patients” 
(n = 60) was formed from the probable fNPH index patients and their relatives with iNPH and a shunt. Everyone in this group had a diagnosed and 
shunted iNPH. The middle and the right part of the figure show how the control group of “Non-iNPH relatives, age ≥ 60” (n = 49) was formed from 
the ≥ 60-year-old relatives of the probable fNPH patients. These relatives were either asymptomatic or had a known etiology for their symptoms 
other than iNPH. *The iNPH patients with symptomatic relative(s) without brain-imaging and their healthy relatives were excluded from the final 
analysis
Table 1 Summary of  the  terms related to  normal pressure hydrocephalus (NPH) and  the  different groups described 
in the paper
Idiopathic normal pressure hydrocephalus (iNPH) The idiopathic form of NPH in general (includes both familial and sporadic subgroups)
Familial idiopathic normal pressure hydrocephalus (fNPH) The familial form of iNPH. An iNPH patient was referred to as a fNPH patient if there were 
multiple iNPH (fNPH) cases in the family (the precise criteria are described in “Methods” 
section)
Sporadic idiopathic normal pressure hydrocephalus An iNPH patient does not have any relatives with iNPH
Secondary normal pressure hydrocephalus (sNPH) NPH caused by a known (acquired) cause, e.g. subarachnoid hemorrhage, brain tumor, 
traumatic brain injury etc.
Non-iNPH relatives In this paper, the probable fNPH patients’ ≥ 60-year-old relatives that had no iNPH (fNPH)
Table 2 INPH-related characteristics of the probable fNPH 
patients (n = 60) included in the final analysis
fNPH familial idiopathic normal pressure hydrocephalus
Self-reported iNPH characteristics n = 60
Gait disturbances 47/57 (82.5%)
Cognitive decline 39/56 (69.6%)
Urinary incontinence 33/57 (57.9%)
Complete triad 23/60 (38.3%)
Shunt response 52/57 (91.2%)
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determined from 44/60 (73%) of the probable and fNPH 
patients and from 22/49 (45%) of their ≥ 60-year-old 
non-iNPH relatives by using quantitative PCR and the 
delta–delta method [27, 28].
Table 3 Comparison of questionnaire data between the probable fNPH patients (n = 60) vs. their ≥ 60-year-old non-iNPH 
relatives (n = 49), from a total of 39 different families
Italic values indicate significance of p value (< 0.05)
The questionnaire included more data but only the more interesting findings are shown in this table
fNPH familial idiopathic normal pressure hydrocephalus, SD standard deviation, F/M female/male, BMI body mass index, AD Alzheimer’s disease, TIA transient ischemic 
attack, COPD chronic obstructive pulmonary disease, CCI Charlson comorbidity index
a Mann-Whitney U test (two-tailed)
b Fisher’s exact test (two-tailed)
Probable fNPH patients (n = 60) Non-iNPH relatives, age ≥ 60 
(n = 49)
p-value
Mean age at questionnaire (± SD) 76.9 (± 7.4) 70.0 (± 8.4) < 0.001a
Sex (F/M) 32/28 (53.3%) 28/21 (57.1%) 0.704b
Mean BMI (± SD) 27.8 (± 4.4) 27.5 (± 5.3) 0.501a
Smoking and alcohol
 Smoker or ex-smoker 16/60 (26.7%) 18/49 (36.7%) 0.302b
 Consumes alcohol 19/60 (31.7%) 31/49 (63.3%) 0.001b
Prevalence of
 APOE ε4 10/45 (22.2%) 8/25 (32.0%) 0.403b
 Loss of CN in intron 2 of SFMBT1 4/44 (9.1%) 2/22 (9.1%) 1.000b
Memory and neurological comorbidities
 Diagnosed AD 10/60 (16.9%) 2/49 (4.1%) 0.061b
 Parkinsonism 2/60 (3.3%) 0/49 (0.0%) 0.501b
 Other diagnosed neurodegenerative disorder 2/59(3.4%) 1/49 (2.0%) 1.000b
 Epilepsy 5/60 (8.3%) 1/49 (2.0%) 0.220b
Cardiovascular comorbidities
 Arterial hypertension 39/60 (65.0%) 21/49 (42.9%) 0.033b
 Diabetes 19/60 (31.7%) 7/49 (14.3%) 0.043b
 Coronary artery disease 8/58 (13.8%) 2/48 (4.2%) 0.108b
 Myocardial infarction 2/58 (3.4%) 0/49 (0.0%) 0.499b
 Cardiac insufficiency 9/58 (15.5%) 1/49 (2.0%) 0.020b
 Cardiac arrhythmia 13/58 (22.4%) 8/41 (16.3%) 0.473b
 Venous thrombosis 6/59 (10.2%) 2/48 (4.2%) 0.292b
 Stroke/TIA 2/58 (3.4%) 2/49 (4.1%) 1.000b
Other comorbidities
 Rheumatoid arthritis 2/59 (3.4%) 2/47 (4.3%) 1.000b
 Spinal stenosis 11/58 (19.0%) 3/48 (6.3%) 0.082b
 Depressive symptoms 19/59 (32.2%) 4/49 (8.2%) 0.004b
 Other mental disease 4/59 (6.8%) 1/49 (2.0%) 0.374b
 Asthma 11/60 (18.3%) 9/49 (18.4%) 1.000b
 COPD 3/60 (5.0%) 1/49 (2.0%) 0.626b
 Peptic ulcer 4/60 (6.7%) 1/49 (2.0%) 0.376b
Hypothyroidism 7/58 (12.1%) 6/49 (12.2%) 1.000b
 Chronic snoring 12/60 (20.0%) 10/49 (20.4%) 1.000b
 Sleep apnea 3/59 (5.1%) 3/48 (6.3%) 1.000b
 Mean modified CC score (± SD) 0.95 (± 1.06) 0.75 (± 1.12) 0.336a
Performance
 Is able to fill the questionnaire independently 27/59 (45.8%) 43/49 (87.8%) < 0.001b
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Modified Charlson comorbidity index
The overall disease burdens in the compared groups 
were measured by using the Charlson Comorbidity 
Index (CCI) [37]. The CCI was slightly modified with 
some assumptions to better fit our research question and 
the data that was available from the questionnaires (see 
Discussion, Strengths and limitations). Modifications 
included: diabetes was considered uncomplicated, cancer 
was considered unmetastasized, liver disease was consid-
ered mild and dementia was excluded.
Statistical analyses
For the statistical analyses, Fisher’s exact test (two-
tailed) was used for the categorical variables and the 
Mann–Whitney U test (two-tailed) for all continuous 
variables, as they were abnormally distributed (signifi-
cance in the Shapiro–Wilk test). The multivariate binary 
logistic regression analysis was used to account for the 
confounding between the clinical variables by using the 
enter method. The clinical variable was included to the 
age adjusted multivariate model if (1) it had a p value 
of < 0.05 in the Fisher’s exact test, (2) it was considered 
fNPH comorbidity, (3) the comorbidity could potentially 
affect the pathogenesis of fNPH. Correlation was tested 
by using the Pearson correlation coefficient. The variables 
in the analyses were based on the data in the question-
naires and the phone interviews, apart from the genomic 
data. The categorical variables were mainly dichotomous. 
P < 0.05 was considered statistically significant. SPSS sta-
tistical software (version 22.0, SPSS INC, Chicago, Illi-
nois) was used to perform the statistical analyses.
Results
The mean age of the probable fNPH patients was higher 
compared to their non-iNPH relatives (76.9 vs. 70.0, 
p < 0.001). Arterial hypertension (65% vs. 43%, p = 0.033), 
diabetes (32% vs. 14%, p = 0.043), cardiac insufficiency 
(16% vs. 2%, p = 0.020) and depressive symptoms (32% vs. 
8%, p = 0.004) were overrepresented among the probable 
fNPH patients compared to their non-iNPH relatives. 
The probable fNPH patients were less likely to consume 
alcohol than their non-iNPH relatives (32% vs. 63%, 
p = 0.001). Only 46% of the probable fNPH patients filled 
the questionnaire independently compared to 88% of the 
non-iNPH relatives (Table 3). The age-adjusted multivar-
iate logistic regression analysis included diabetes, cardiac 
insufficiency and arterial hypertension as these comor-
bidities were considered to potentially contribute to the 
pathogenesis of iNPH. Only a weak correlation was found 
between these four clinical variables (Pearson correlation 
coefficient, R < 0.34). In the multivariate analysis, age at 
questionnaire (OR = 1.1, 95% CI 1.1–1.2, p < 0.001) and 
diabetes (OR = 3.8, 95% CI 1.1–12.9, p = 0.030) remained 
independently significant (Table 4).
No significant differences were found in the prevalence 
of APOE ε4 (22% vs 32%, p = 0.403) or the CN loss in 
intron 2 of SFMBT1 (9% vs 9%, p = 1.000) (Table 3), but 
diabetes was present in 3 out of the 4 probable fNPH 
patients that had CN loss in the SFMBT1 gene compared 
to none out of 2 of the non-iNPH relatives.
Discussion
Diabetes
The most important finding of this study is the tendency 
towards increased prevalence of the cardiovascular 
comorbidities, especially diabetes, in the fNPH patients 
compared to their non-iNPH relatives. Although the age 
difference between the two groups was nearly 7  years, 
diabetes remained independently significant in the mul-
tivariate model when adjusted to age, whereas arterial 
hypertension or cardiac insufficiency did not. Previous 
studies have compared the differences in the prevalence 
of diabetes between the iNPH patients and the healthy 
controls with comparable age distribution [7–14]. Using 
a table from the review by Hudson et al. [38] that sum-
marized the results of seven of these studies, we can 
calculate the pooled prevalence of diabetes among the 
iNPH patients and the controls. In these seven studies 
the pooled diabetes rates in iNPH were 24% compared 
to 10% in the controls, prevalence ratio 2.4:1, p < 0.001 
(χ2-test) (only 70–90-year-olds included from the Eide 
and Pripp’s study [11]). Our results with the novel study 
design closely agree with these previous results when 
it comes to iNPH (32% vs. 14%; prevalence ratio 2.3:1). 
Additionally, in our previous study [25], no significant 
Table 4 Logistic regression analysis comparing 
the  probable fNPH patients (n = 60) and  their non-iNPH 
relatives, age ≥ 60 (n = 49) as a reference category
Italic values indicate significance of p value (< 0.05)
Hosmer–Lemeshow = 0.189; Overall percentage = 75.7%
fNPH familial idiopathic normal pressure hydrocephalus, OR odds ratio, CI 
confidence interval
Clinical variable n Model OR 95% CI p-value
Age at question-
naire
109 Univariate 1.121 1.057–1.189 < 0.001
107 Multivariate 1.123 1.061–1.189 < 0.001
Diabetes 109 Univariate 2.780 1.057–7.317 0.038
107 Multivariate 3.840 1.142–12.912 0.030
Cardiac insuffi-
ciency
107 Univariate 8.816 1.075–72.282 0.043
107 Multivariate 4.250 0.475–38.030 0.196
Arterial hyperten-
sion
109 Univariate 2.476 1.140–5.378 0.022
107 Multivariate 1.147 0.444–2.959 0.777
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differences were found in the prevalence of diabetes 
between the sporadic iNPH and the fNPH patients.
Other cardiovascular risk factors, including arterial 
hypertension, dyslipidemia, obesity and physical inac-
tivity have been also found to be overrepresented in the 
iNPH patients [7, 9–13, 15], suggesting that they could be 
possible risk factors for the development of iNPH. This is 
also backed by the finding of cerebral microbleeds being 
detected more often in the iNPH patients in magnetic 
resonance imaging (MRI), and thus a vascular compo-
nent could possibly affect the pathophysiology of iNPH 
[39]. A recent study that compared four different types of 
adult hydrocephalus (transitional, unrecognized congeni-
tal, acquired and iNPH) found out that the prevalence of 
cardiovascular comorbidities in iNPH was significantly 
higher compared to the other types [40]. This finding 
together with the later onset age of iNPH indicates that 
the cardiovascular comorbidities could have a chronic 
effect on its development.
There is evidence that the glymphatic system dysfunc-
tion could affect the development of iNPH [41–43]. It 
has been suggested that in iNPH the glymphatic system 
is possibly impaired through neuroinflammation, reac-
tive astrogliosis, depolarization and reduced density of 
aquaporin-4 (AQP4) and sleep disturbances, which could 
reduce the normal clearance of CSF [43–45]. Interest-
ingly in rat models, diabetes has been found to cause 
glymphatic system dysfunction, reduction in AQP4 den-
sity, neuroinflammation, microvascular damage, blood–
brain barrier damage and cognitive decline that could be 
associated with glymphatic system dysfunction [46–49]. 
It seems that diabetes could also cause astrogliosis and 
dysregulated metabolism in astrocytes in mouse and rat 
models [49]. By affecting the astrocytes diabetes has also 
been found to reduce the glutamate uptake in brain in rat 
models [50, 51]. Interestingly, iNPH patients have been 
found to suffer from corticospinal hyperexcitability and it 
has been hypothesized to possibly derive from increased 
activity of glutamatergic system [52, 53].
Some studies have also found the iNPH patients to 
suffer from a decreased cerebral metabolic rate of glu-
cose [54], reduced thalamic N-acetylaspartate and total 
N-acetylaspartate, an important metabolite in the cen-
tral nervous system [55], and the down-regulation of the 
adenosine receptors that together with adenosine are 
important for the vascular protection and the modula-
tion of inflammation [56]. This together with the high 
prevalence of cardiovascular comorbidities shows that 
metabolic dysfunction seems to be present in iNPH and 
potentially also in fNPH. On the other hand, it has also 
been suggested that diabetes in iNPH could be a conse-
quence of ventriculomegaly and compression damage to 
the hypothalamic pituitary axis causing hormonal imbal-
ances [38].
The questionnaire did not classify the type of diabetes 
the participants had. We can assume that nearly all of the 
cases were type 2 diabetes (T2DM) since the overall prev-
alence of T2DM among the elderly is remarkably higher 
than type 1 diabetes (T1DM) [57]. We would expect the 
rationale about iNPH/fNPH, cardiovascular risk factors 
and diabetes to hold true at least in T2DM, T1DM and 
latent autoimmune diabetes in adults (LADA) but there 
seems to be only very few studies concerning NPH and 
the different types of diabetes other than T2DM. One 
reason could be that the life expectancy of a patient with 
T1DM used to be quite poor in the past compared to the 
average onset age of iNPH [58]. In one study, a possible 
presence of NPH was found in 6 insulin-dependent dia-
betic patients with recurrent hypoglycemic coma (mean 
age 62, mean diabetes duration 25 years) [59]. Their dia-
betes types were not precisely classified in the study but 
most likely either T1DM, LADA or progressed T2DM.
These findings support the idea that diabetes could 
impact the development of iNPH and fNPH and even 
its phenotype. However, it is unclear how significant this 
impact is as the majority of iNPH patients do not seem 
to have diabetes although it being clearly overrepre-
sented in iNPH compared to the general population. It 
is also unclear whether the treatment or the prevention 
of certain metabolic dysfunctions or the cardiovascular 
comorbidities would effectively prevent the development 
of iNPH/fNPH or if there were other factors affecting 
it. Especially the potential genetic aspect of diabetes in 
iNPH/fNPH is intriguing and warrants further research.
Depressive symptoms
Symptoms of depression have been found to be common 
among the iNPH patients in previous studies [60–62], 
which is in line with our findings. Depression itself is 
probably not an independent risk factor for the develop-
ment of iNPH but more likely a result of the increased 
disability due to iNPH or other comorbidities that may 
contribute to the pathogenesis of iNPH or to the develop-
ment of depression itself [60–62]. It might be that iNPH 
is associated with an extensive range of psychiatric symp-
toms [14, 15] supported by our recent report indicating 
that schizophrenia is more common in the iNPH patients 
compared to the general population [63]. Further pro-
spective studies regarding the symptoms of depression 
and iNPH are needed.
The identified relatives
When it comes to the excluded iNPH patients with 
symptomatic relatives that had no brain-imaging avail-
able to confirm the relative’s iNPH, the family history is 
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usually based on either symptomatic mother, father or 
sibling that has already died. It is plausible that some of 
these potential fNPH cases are actually sporadic. After 
all, it would be interesting to study both symptomatic and 
asymptomatic relatives of iNPH patients regardless of the 
prior family history on potential NPH-related symptoms, 
although the probability of finding genetic risk factors 
could be notably higher in those with clear family history. 
A consensus on determining the diagnosis of fNPH is 
needed considering that full consensus of definite iNPH 
diagnosis is actually also lacking.
The pedigrees offer a novel opportunity to study the 
genetics and the pathophysiology of iNPH/fNPH. In addi-
tion to this, when we learn more about the development 
of iNPH, it allows us to possibly detect the relatives who 
are at a greater risk of developing iNPH and to potentially 
achieve a preclinical diagnosis of iNPH, as iNPH seems 
to show signs of asymptomatic ventriculomegaly (AVIM) 
in the neuroradiological imaging years before the clinical 
symptoms appear [64, 65]. This could be important since 
delayed shunting seems to hamper the clinical outcome 
of iNPH [66]. INPH is quite an unknown disorder among 
the general population but the knowledge of a possible 
familial aggregation of iNPH (fNPH) might allow the rel-
atives to detect the symptoms of NPH more easily and to 
potentially seek treatment before the symptoms progress 
severely.
Alcohol, sleep apnea, SFMBT1 and APOE ε4
Alcohol consumption was recently suggested to be a 
potential risk factor for iNPH in two studies [14, 67]. Our 
results don’t back up this finding, but it must be noted 
that our questionnaire represents only the time close to 
the diagnosis and not their alcohol consumption earlier 
in life. Also, a frequent association between iNPH and 
obstructive sleep apnea has been found [45]. Our analysis 
with the probable fNPH families showed no differences 
in the prevalence of sleep apnea between the groups 
(Table 3).
An interesting finding in the study was the similar 
prevalence of the CN loss in intron 2 of the SFMBT1 gene 
between the fNPH patients and their non-iNPH relatives 
(9% vs. 9%), despite the allelic variation in SFMBT1 being 
discovered to be overrepresented in the iNPH patients in 
a Japanese study cohort [27] and also in Finnish and Nor-
wegian cohorts [28]. This is the first time the SFMBT1 
CN loss has been directly compared between the fNPH 
patients and their relatives. Korhonen et  al. [28] found 
the SFMBT1 CN loss to be present in 5% of the gen-
eral Finnish population, which is less than it was in the 
non-iNPH relatives of these probable fNPH patients. We 
can speculate whether the SFMBT1 CN loss accumu-
lates in these families exposing them to a greater risk of 
developing iNPH. The SFMBT1 CN loss might require 
some other unknown external factor to trigger the devel-
opment of iNPH, and interestingly in this study, diabetes 
was present in 3 out of the 4 probable fNPH patients that 
had CN loss in the SFMBT1 gene compared to none out 
of 2 of the non-iNPH relatives. This indicates that diabe-
tes might be one potential trigger that is needed for the 
CN loss in intron 2 of SFMBT1 to cause iNPH and raises 
a question for further study on the potential gene-envi-
ronmental interactions. The brain MRIs of these elderly 
relatives with the CN loss in SFMBT1 in this study would 
be beneficial to exclude the possibility of asymptomatic 
ventriculomegaly [64, 65]. It must be noted that the num-
ber of the SFMBT1 genotyped relatives in this study is 
small, so pure coincidence could have possibly affected 
the results. More studies concerning the mechanism 
between SFMBT1 and iNPH are needed.
APOE ε4 did not show any association with fNPH 
when compared to the relatives (22% vs. 32%). This is 
in-line with the previous findings [31, 32] and strength-
ens the assumption that fNPH has a genetic background 
independent from AD. From the probable fNPH patients 
suffering from comorbid AD, 50% were carriers of APOE 
ε4 in this study group.
Strengths and limitations
The main strengths of this study are that only the prob-
able fNPH families with multiple confirmed cases were 
included in the analysis and the families came from a 
fairly homogeneous population. The questionnaires were 
well-filled as the modified CCI scores were measurable 
from 93% of the probable fNPH patients and 98% of the 
non-iNPH relatives included in the final analysis. The 
questionnaires sent to the patients and to their relatives 
were also identical and therefore the results were closely 
comparable.
There are limitations and potential sources of error. 
The data used was based on the questionnaires that were 
filled by the participants themselves or by their next of 
kin, which might create a potential source of error. The 
phone-interview-based data recruitment of the relatives 
to the study is not the most effective and reliable method. 
Due to the nature of iNPH, dementia was excluded from 
the modified CCI as it would probably have caused bias. 
The variables in the study were mainly dichotomous, and 
therefore assumptions concerning diabetes and cancer in 
the CCI measurements were made as we have little infor-
mation about the severity of the comorbidities, which 
requires further study.
Significance of the research and future perspectives
This is the first comparison of familial iNPH patients 
and their elderly non-iNPH relatives that includes 
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multiple families. This data is important when deci-
phering the pathophysiology and the genetics behind 
iNPH in the future. These results show that the fNPH 
patients and their elderly non-iNPH relatives seem to 
differ from each other, and therefore there must be an 
as-yet-unknown explanation for why some of the fam-
ily members develop iNPH while the others do not. 
This study also supports the previous findings that the 
overrepresentation of cardiovascular comorbidities 
and depressive symptoms are associated with iNPH, 
as being conducted from a familial standpoint. Due to 
our small sample size, it would be beneficial to repli-
cate these findings with a larger sample size. Consider-
ing the relative rarity of fNPH international multicentre 
studies are needed in the future.
Conclusions
Diabetes was independently associated with fNPH in 
the study. The diabetes rates were in-line with the previ-
ous iNPH studies. Diabetes has previously been found to 
cause neuroinflammation, altered brain metabolism and 
microvascular damage. It has also been found to impair 
the glymphatic system and to cause reduction in AQP4 
density in rat models, which could disturb the normal 
clearance of the CSF. Therefore, diabetes might be an 
independent risk factor for the development of iNPH/
fNPH. It is unclear how effective the treatment or the 
prevention of diabetes itself would be in preventing the 
possible development of iNPH or improving the outcome 
of a shunt surgery. It is also unclear what is the impact of 
potential gene-environmental interactions when it comes 
to diabetes and iNPH/fNPH. The identified pedigrees 
offer a novel opportunity to study the genetics behind 
iNPH and to possibly achieve preclinical diagnoses of 
iNPH.
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